Article

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04

2023-11-03

Abstract excerpt

<h4>ABSTRACT</h4> Drug resistance poses a significant challenge in the development of effective therapies against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and M49K/S301P, in the 3C-like protease (3CLpro) that confer resistance to a novel non-covalent inhibitor, WU-04. Crystallographic analysis indicates that the M49K mutation destabilizes the WU-04 binding pocket, impacting the binding of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 57d0ef70-5cc5-5914-a675-e24171d3fe31
DOI: 10.1101/2023.11.01.564972

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04DOI 10.1101/2023.11.01.564972Read

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04Semantic proximity Read

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.Semantic proximity Read

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor <i>in vitro</i> and confer resistance to nirmatrelvirSemantic proximity Read

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read

Inhibitor-induced dimerization mediates lufotrelvir resistance in mutants of SARS-CoV-2 3C-like protease.Semantic proximity Read

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 VariantsSemantic proximity Read

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity Read

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read

Structural basis for varying drug resistance of SARS-CoV-2 Mpro E166 variants.Semantic proximity Read

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read